• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors

    2/14/22 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care
    Get the next $SSKN alert in real time by email

    HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors.

    Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions.

    "We are delighted to welcome Patty to STRATA's board. Her firsthand experience as a practicing dermatologist coupled with her deep experience in the development and launch of pharmaceuticals, medical devices and biologics brings tremendous value to the Company's leadership team and is an ideal fit for the board of directors at STRATA Skin Sciences," said William D Humphries, Executive Chairman of STRATA's Board of Directors. "Her veteran counsel, particularly in the areas of Research and Development and operational excellence, will greatly benefit STRATA as we continue to expand our commercial footprint in the dermatology space."

    From 2015 to 2018, Dr. Walker served as the President and Chief Scientific Officer of Brickell Biotech Inc. where she oversaw the research and development, regulatory, compliance, chemistry, and manufacturing efforts for the company's product portfolio. Currently, Dr. Walker is the founder and president of Walker Consulting, serves as a supervisory board member at Merz pharmaceuticals, serves on the board of directors at Forte Biosciences Inc, and is the Medical Director and solo practitioner of Walker Dermatology. Prior, she served on the board of Neothetics, Inc. and as an advisor to the board of directors at Kythera Biopharmaceuticals, Inc.

    Dr. Walker has served in multiple roles, throughout her career, including Chief Medical Officer at Kythera Biopharmaceuticals. While there, she led research efforts focused on the development of novel, first in class medical devices and pharmaceutical products for dermatologic and aesthetic medicine. Before Kythera, Dr. Walker was the Chief Medical Officer at Allergan Medical where her primary research efforts surrounded the development of alternative hyaluronic acid fillers for facial rejuvenation. She was Executive Vice President and Chief Scientific Officer at Inamed, which was acquired by Allergan in 2006. While there, she researched biological toxins, dermal filler substances, bariatric and silicone gel filled breast implants. Dr. Walker has also held various positions at Allergan where she conducted clinical and translation research in skin care and oncology. Prior to which, she was a clinical faculty member at the University of California Irvine in the department of dermatology and completed a research fellowship at the National Institute of Health's Dermatology Branch.

    "I am looking forward to joining STRATA's board, as I believe they have an outstanding opportunity to make a difference in the way dermatological disease is treated and further improve patient outcomes," said Dr. Walker. "STRATA has long been a leader in the treatment of dermatologic conditions, and I am excited to contribute my expertise to the company as they head into their next phase of growth."

    Dr. Walker completed her medical degree and dermatology residency training from the University of Iowa College of Medicine and received her B.S. in General Science from the University of Iowa. Dr. Walker is a board-certified dermatologist specializing in medical and aesthetic dermatology.

    About STRATA Skin Sciences, Inc.

    STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the in-office treatment of dermatologic conditions. Its products include the XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.

    The Company's proprietary XTRAC and recently acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents.

    STRATA's unique business model in the US leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company's partner dermatology clinics.

    Investor Contact

    Jack Droogan

    (203) 585-4140

    [email protected] 



    Primary Logo

    Get the next $SSKN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SSKN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SSKN
    SEC Filings

    View All

    Strata Skin Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    8/18/25 8:00:51 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Strata Skin Sciences Inc.

    10-Q - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    8/13/25 9:06:36 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Strata Skin Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    8/13/25 5:15:38 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

    HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update. Second Quarter Highlights Historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseases, effectively tripling the covered patient population in the USPotential acceleration of expanded reimbursement coverage through application for G-codes to gain access by 2026 cycleSubmission of econom

    8/13/25 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences Moves to Accelerate Medicare and Private Payer Coverage from Expanded CPT Code Expansion, Tripling Addressable Market to 30M+ Patients

    Peer-reviewed publications continue to validate Excimer Laser efficacy in vitiligo and treatment STRATA updates status of non-Excimer laser false advertising litigation HORSHAM, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced it is working with the Centers for Medicare & Medicaid Services (CMS) to obtain temporary codes that would accelerate access to recently expanded reimbursement for its XTRAC® excimer laser treatment. As previously announced, the American M

    8/7/25 8:15:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update

    HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Wednesday, August 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, i

    7/31/25 8:15:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Geiger Uri bought $723,999 worth of shares (230,573 units at $3.14) (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    7/17/24 5:08:57 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Large owner Accelmed Partners, L.P. bought $723,999 worth of shares (230,573 units at $3.14), increasing direct ownership by 19% to 1,441,835 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    7/17/24 5:08:11 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Rafaeli Dolev bought $59,974 worth of shares (19,100 units at $3.14), increasing direct ownership by 15% to 143,156 units (SEC Form 4)

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    7/17/24 5:01:09 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Gov Shmuel

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    5/15/25 5:21:12 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Accounting Officer Gillings John T

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    5/15/25 5:14:28 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Executive Officer Rafaeli Dolev

    4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)

    5/15/25 5:09:40 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Leadership Updates

    Live Leadership Updates

    View All

    Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer

    Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and

    11/28/23 8:30:00 AM ET
    $APYX
    $PDSB
    $SSKN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    STRATA Skin Sciences Appoints Dr. Uri Geiger to Chairman of its Board of Directors

    HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera

    6/30/23 8:00:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences Appoints Patricia S. Walker, M.D., Ph.D. to its Board of Directors

    HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT

    2/14/22 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Financials

    Live finance-specific insights

    View All

    STRATA Skin Sciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

    HORSHAM, Penn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended June 30, 2025, and provides a corporate update. Second Quarter Highlights Historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseases, effectively tripling the covered patient population in the USPotential acceleration of expanded reimbursement coverage through application for G-codes to gain access by 2026 cycleSubmission of econom

    8/13/25 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences to Report Second Quarter 2025 Financial Results on August 13, 2025 and Provide Corporate Update

    HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 after the market close. STRATA management will subsequently host a conference call at 4:30 p.m. ET on Wednesday, August 13, 2025 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, i

    7/31/25 8:15:00 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    STRATA Skin Sciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

    HORSHAM, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2025, and provides a corporate update. First Quarter 2025 Financial Highlights Revenue in the first quarter of 2025 was $6.8 million, up 1% Global net recurring XTRAC® revenue in the first quarter was $4.5 million vs. $4.6 million in the prior year period, with international growth of 27% offsetting a 4% decline in the domestic marketAverage net revenue per dome

    5/14/25 4:05:00 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $SSKN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Strata Skin Sciences Inc.

    SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

    11/14/24 2:04:43 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Strata Skin Sciences Inc.

    SC 13D/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

    7/18/24 7:42:09 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Strata Skin Sciences Inc. (Amendment)

    SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)

    2/14/24 4:51:41 PM ET
    $SSKN
    Medical/Dental Instruments
    Health Care